Advanced detection of sepsis

• US 10,221,453 B2
• Filed: 02/05/2018
• Issued: 03/05/2019
• Est. Priority Date: 04/03/2008
• Status: Active Grant

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Shi, Song, Moore, Richard L., Garrett, James
• Primary Examiner(s): Cook, Lisa V
• Application Number:
  US15/889,035
• Publication Number:
  US 20180305758A1
• Time in Patent Office: 393 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/90209 acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
• CPC Class Codes: G01N 2333/91051 Acyltransferases other than aminoacyltransferases (general) (2.3.1)
• CPC Class Codes: G01N 2800/26 Infectious diseases, e.g. generalised sepsis
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject.

Claims

1. A method of treating a subject likely to develop sepsis comprising the steps of:

(a) obtaining a measurement at a plurality of time points, prior to laboratory confirmation of a clinically significant infection causative of sepsis, of an amount of a compound according to formula (I)

2. The method of claim 1, wherein R is saturated acyl.

3. The method of claim 1, wherein R is C₁₄-C₂₂ acyl.

4. The method of claim 1, wherein R is C₁₆-C₂₀ acyl.

5. The method of claim 1, wherein R is C₁₆-C₁₈ acyl.

6. The method of claim 1, wherein R is C₁₆ saturated acyl.

7. The method of claim 1, wherein R is C₁₈ saturated acyl.

8. The method of claim 1, wherein R is unbranched C₁₆-C₁₈ acyl.

9. The method of claim 1, wherein R is palmitoyl.

10. The method of claim 1, wherein R is stearoyl.

11. The method of claim 1, wherein the amount of a compound according to formula (I) is measured 12, 24, 36 or 48 hours prior to the onset of sepsis in said SIRS-positive patient.

12. The method of claim 1, wherein the one or more biomarkers comprise procalcitonin.

13. The method of claim 12, wherein the one or more clinical markers of the SIRS-positive subject comprises respiratory rate and temperature.

14. The method of claim 1, wherein the one or more clinical markers of the SIRS-positive subject comprises respiratory rate and temperature.

15. The method of claim 1, wherein the one or more biomarkers in fluid or tissue of the SIRS-positive subject comprises TRAF-interacting protein with a forkhead-associated domain (TWA), extra-hepatic arginase (ARG2), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), and human leukocyte antigen—

antigen D-related alpha chain (HLA-DRA).

16. The method of claim 1, wherein the one or more clinical markers of the SIRS-positive subject comprises respiratory rate or temperature, and the one or more biomarkers comprises HLA-DRA.